Dyslipidemia, a widespread and growing chronic blood lipid disorder, poses a significant hurdle in developing nations due to its complex biological variations. The standard approach—measuring blood fats and prescribing traditional drugs such as statins, ezetimibe, and fibrates—often falls short in terms of effectiveness, patient compliance, and side effects. Even newer, highly effective treatments such as PCSK9 inhibitors are prohibitively expensive. This research aims to find better solutions by applying advanced molecular biology and “Omics” technologies, including genomics, proteomics, and metabolomics. These technologies are crucial for understanding the disorder’s intricate genetic underpinnings, interactions between metabolites and protein expression, which in turn facilitates the development of more precise, targeted treatments such as monoclonal antibodies and RNA-based therapies. Specifically, single-cell analysis (SCA), particularly techniques such as single-cell RNA sequencing (scRNA-seq), is becoming an influential tool. It allows researchers to investigate the disease’s heterogeneity at the individual cell level, offering unprecedented insights into its development and helping pinpoint new therapeutic targets. While SCA still contends with challenges related to its cost, the complexity of the data, and technical difficulties in isolating cells, ongoing technological progress is rapidly expanding its potential. The ultimate goal is to leverage SCA to create safer, more effective, and personalized drugs for dyslipidemia.